Company / Revenue per Share
Taysha Gene Therapies, Inc. Revenue per Share History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$0.05
FY2025
5-year range
$0.04 / $0.08
FY2022-FY2025
Trend
-42.3%
vs FY2024
Sector context
#141 of 154
Health Care
What the data says
Among 154 Health Care companies, Taysha Gene Therapies, Inc. is in the bottom 8% for revenue per share. Improved from $0.04 to $0.05 over the past 2 years.
Based on SEC 10-K filings.
0.05 in FY2025 with a 3-year CAGR of -9.8%.
Improved from $0.04 to $0.05 over the past 2 years.
Health Care sector context is included.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- -9.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 154This company $0.05 Sector average $15.09
▼
-99.7% below sector average
Key checks
Key Insights
- In FY2025, revenue per share decreased 42.3% year-over-year.
- Ranks #141 out of 154 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.05 | -42.3% |
| FY2024 | $0.08 | +108.8% |
| FY2023 | $0.04 | -39.1% |
| FY2022 | $0.07 | - |
| FY2021 | - | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026